You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a novel highly effective influenza vaccine

    SBC: FLUGEN INC            Topic: NIAID

    DESCRIPTION provided by applicant Seasonal influenza flu virus an NIAID category C priority pathogen causes widespread infection resulting in at least million cases of severe illness and deaths worldwide Young children and elderly or immunocompromised individuals are typically at greater risk of severe illness or death from influenza Newly emerging strains can result ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. New small molecule inhibitors of arenaviruses

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. STTR Phase I: Robotic Leg Advancement Device

    SBC: AndrosRobotics LLC            Topic: EI

    This Small Business Technology Transfer Research (STTR) Phase I project seeks to develop a novel, intelligent device for automation of gait training in the neurological patient population undergoing physical therapy and rehabilitation. The objective of this project is the creation of a physically simple robotic system, which uses a sophisticated control system to intelligently cooperate with the p ...

    STTR Phase I 2014 National Science Foundation
  6. STTR Phase I: Ferrofluidic enclosures for enhanced control of thermal and magnetic fields in spin-stabilized atomic micro-devices

    SBC: COMMET LLC            Topic: EW

    The broader impact/commercial potential of this project is determined by new consumer products and new industries which would flourish on portable and reliable atomic clocks, gyroscopes, and magnetometers when they become available. Proposed compact thermal and magnetic enclosure reduces the most bulky part of such devices and provides an avenue for further miniaturization. A chip-scale atomic clo ...

    STTR Phase I 2014 National Science Foundation
  7. STTR Phase I: Software-Based Building Airflow Analysis Tool for Enabling HVAC Energy Use Savings in Commercial Buildings

    SBC: Aeolus Building Efficiency Inc            Topic: BC

    This Small Business Technology Transfer (STTR) Phase I project will establish proof of concept for a unique, software-based Building Airflow Analysis Tool for measuring and optimizing airflow rates in commercial buildings. Using the existing Building Automation System (BAS), room temperature responses to controlled perturbations of airflow rates are used with a physics-based room thermal model and ...

    STTR Phase I 2014 National Science Foundation
  8. STTR Phase I: Silver Replacement for Conductive Inks

    SBC: Microreactor Solutions LLC            Topic: NM

    This Small Business Innovation Research (SBIR) Phase I project will develop new materials to replace silver in conductive ink applications. Current silver replacement materials all have significant drawbacks making them unsuitable for use in many industries which would benefit from these cost savings. The project will utilize advanced thin film nanocoatings to produce silver replacement materials ...

    STTR Phase I 2014 National Science Foundation
  9. STTR Phase I: Carbon Nanotube Enabled High-Temperature Wireless Sensor System

    SBC: ENGENIUSMICRO LLC            Topic: EI

    This Small Business Technology Transfer Research (STTR) Phase I project will develop innovative sensors based on vertically aligned carbon nanotube (CNT) diode structures to increase the range and performance of wireless microelectromechanical systems (MEMS) sensors in high-temperature environments. Currently, wireless sensors are limited by the need to protect the electronics from the sensor envi ...

    STTR Phase I 2014 National Science Foundation
  10. NMDA Receptor Subtype Selective Modualtors as Alzheimer's Disease Therapeutics

    SBC: NEUROP, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a devastating neurodegenerative disorder. One of the few drugs used to treat AD is memantine, which inhibits N-methyl-d-aspartate receptors (NMDARs), glutamate receptor subtypes found at nearly all vertebrate excitatory synapses. NMDARs are critically involved in many aspects of nervous system function, including learning and me ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government